Multiple Myeloma-specific universal CAR T cells(Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2023/08/28 20:00:45

Base Information

Drug NameMultiple Myeloma-specific universal CAR T cells(Shenzhen Geno-Immune Medical Institute)
Drug Alias NameMM-specific universal CAR T cells(Shenzhen Geno-Immune Medical Institute)Universal CAR-T Cells(Shenzhen Geno-Immune Medical Institute)Multi-CAR T Cell Therapy(Shenzhen Geno-Immune Medical Institute)Multiple Antigen-specific CAR T Cells Therapy(Shenzhen Geno-Immune Medical Institute)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Geno-Immune Medical InstituteBeijing Jingdu Children's HospitalSecond Affiliated Hospital Of Hainan Medical University
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Geno-Immune Medical Institute
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A